Interneuron/Wyeth-Ayerst Redux Phase IV advisory cmte. review likely to occur in February.
Executive Summary
INTERNEURON REDUX PHASE IV ADVISORY CMTE. REVIEW LIKELY FOR FEBRUARY, following the postponement of the previously scheduled Nov. 22 meeting of FDA's Endocrinologic & Metabolic Drugs Advisory Committee to discuss postmarketing studies for the anti-obesity drug Redux (dexfenfluramine). The agenda for the committee's Dec. 10-11 meeting is filled, but the committee is tentatively scheduled to meet again on Feb. 20-21.